REGENXBIO Inc.
RGNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, REGENXBIO Inc. focuses on Biotechnology services and products. REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Valued at $590.2M, RGNX is a small-cap name in its sector. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Market Cap
$590.2M
Beta
0.93
P/E (TTM)
—
P/E (Fwd)
-2.98
EPS (TTM)
$-3.78
EPS (Fwd)
$-3.00
ROE
-137.6%
ROA
-21.2%
Cash
$105.5M
Total Debt
$250.5M
Free CF
-$184.3M
52W Change
-9.6%
Annual Financials
Cash vs Debt
Where RGNX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, RGNX finished 0.11% above its 150-day moving average ($9.31) and 10.04% below its 200-day moving average ($10.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RGNX overbought or oversold?
At the September 2, 2026 close, RGNX's RSI(14) was 40.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
REGENXBIO Inc. carries $250.5M in total debt against $105.5M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$184.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -137.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $112.7M to $170.4M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RGNX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.